Effect of a heat shock protein 90‑specific inhibitor on the proliferation and apoptosis induced by VEGF‑C in cervical cancer cells

Experimental and Therapeutic Medicine

Volumn 8, Issue 5, 2014, Pages 1559-1564

  Du, Xue ^a   Li, Yongmei ^a   Jing, Xu ^b   Zhao, Lina ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

Apoptosis; Cervical cancer; Heat shock protein 90; Proliferation; Vascular endothelial growth factor C

Indexed keywords

CYCLIN D1; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROPLATE READER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 84907854513     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1930     Document Type: Article

References (23)

1. Bishop SC, Burlison JA and Blagg BS: Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 7: 369-388, 2007.
2. Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549, 2010.
3. Chiosis G, Dickey CA and Johnson JL: A global view of Hsp90 functions. Nat Struct Mol Biol 20: 1-4, 2013.
4. Lee WY, Chen YC, Shih CM, et al: The induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide. Toxicol Appl Pharmacol 274: 55-62, 2014.
5. Schwock J, Pham NA, Cao MP and Hedley DW: Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 61: 669-681, 2008.
6. Neckers L: Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol 172: 259-277, 2006.
7. Mehta PP, Kung PP, Yamazaki S, et al: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Lett 300: 30-39, 2011.
8. Du X and Mi R: Study on the cell signal transductions of cell proliferation and apoptosis induced by VEGF-C in cervical carcinoma. Xian Dai Fu Chan Ke Za Zhi 11: 877-880, 885, 2011.
9. Chinnaiyan P, Allen GW and Harari PM: Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 16: 59-64, 2006.
10. Park JW, Yeh MW, Wong MG, et al: The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88: 3346-3353, 2003.
11. Sreedhar AS, Kalmár E, Csermely P and Shen YF: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562: 11-15, 2004.
12. Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81: 15-27, 2007.
13. Polier S, Samant RS, Clarke PA, et al: ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 9: 307-312, 2013.
14. Richter K and Buchner J: Hsp90: chaperoning signal transduction. J Cell Physiol 188: 281-290, 2001.
15. Cappello F, David S, Rappa F, et al: The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 5: 139, 2005.
16. Powers MV and Workman P: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 (Suppl 1): 125-135, 2006.
17. Georgakis GV, Li Y, Rassidakis GZ, et al: Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12: 584-590, 2006.
18. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Antimyeloma activity of heat shock protein-90 inhibition. Blood 107: 1092-1100, 2006.
19. Ferrario A, Rucker N, Wong S, Luna M and Gomer CJ: Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 67: 4989-4995, 2007.
20. Röhl A, Rohrberg J and Buchner J: The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci 38: 253-262, 2013.
21. Sidera K and Patsavoudi E: HSP90 Inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov 9: 1-20, 2014.
22. Gooljarsingh LT, Fernandes C, Yan K, et al: A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA 103: 7625-7630, 2006.
23. Duus J, Bahar HI, Venkataraman G, et al: Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 47: 1369-1378, 2006.